RESEARCH PAPER
Application of artificial neural networks to accurately predict non-HDL-C levels based on LDL-C and triglycerides
 
More details
Hide details
1
Department of Biopharmacy, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
 
 
Submission date: 2025-10-13
 
 
Final revision date: 2026-02-26
 
 
Acceptance date: 2026-02-26
 
 
Online publication date: 2026-05-25
 
 
Publication date: 2026-05-25
 
 
Corresponding author
Anna Badura   

Department of Biopharmacy, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Jurasza 2, 85-089, Bydgoszcz, Poland
 
 
Pol. Ann. Med. 2026;33:135-140
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
While LDL-C concentration remains a key indicator in lipid profile assessment and cardiovascular risk prediction, non-HDL cholesterol (non-HDL-C) was acknowledged as a superior marker, particularly among people with elevated levels of triglycerides (TG). However, non-HDL-C is not always calculated or reported in laboratory panels.

Aim:
The main purpose of this study is to evaluate the effectiveness of artificial neural networks (ANNs) in predicting non-HDL-C levels based on standard lipid parameters, i.e. LDL-C and TG.

Material and methods:
Based on 26,914 anonymized lipid profiles (total cholesterol [TC], TG, LDL-C, non-HDL-C), an MLP 2-4-1 neural network was trained to estimate non-HDL-C values.

Results and discussion:
The non-HDL-C values predicted by the model showed a strong correlation with laboratory results (R² = 0.944 overall). Correlation was slightly higher for TG < 400 mg/dL (R² = 0.945) and remained relatively high in the hypertriglyceridemic subgroup (R² = 0.896).

Conclusions:
This study demonstrates that artificial neural networks are able to accurately estimate non-HDL-C values using the results of lipid parameters survey, even in the cases of severe hypertriglyceridemia. Given its high prediction accuracy and its simplicity, the model is promising for the future as a practical decision-support tool in cardiovascular risk assessment, especially where non-HDL-C is unavailable or unreported.
REFERENCES (17)
1.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75:429.
 
2.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
 
3.
Nanchen D, Tokgozoglu L, Komen JJ, Bardet A, Catapano AL, Ray KK. Contemporary LDL-cholesterol management in male and female patients at high-cardiovascular risk: Results from the European observational SANTORINI study. Eur Heart J. 2024.
 
4.
Zeng S, Wang H, Li X, et al. Composition design of fullerene-based hybrid electron transport layer for efficient and stable wide-bandgap perovskite solar cells. J Energy Chem. 2025;102:172–178.
 
5.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
 
6.
Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020;5:540–548.
 
7.
Virani SS. Non-HDL cholesterol as a metric of good quality of care: Opportunities and challenges. Tex Heart Inst J. 2011;38:160–162.
 
8.
Romaszko J, Gromadziński L, Buciński A. Friedewald formula may be used to calculate non-HDL-C from LDL-C and TG. Front Med (Lausanne). 2023;10:1247126.
 
9.
Kruse R, Mostaghim S, Borgelt C, Braune C, Steinbrecher M. Multi-layer perceptrons. Computational intelligence: A methodological introduction: Springer; 2022:53–124.
 
10.
Weiss R, Karimijafarbigloo S, Roggenbuck D, Rödiger S. Applications of Neural Networks in Biomedical Data Analysis. Biomedicines. 2022;10.
 
11.
Ramchoun H, Idrissi MAJ, Ghanou Y, Ettaouil M. Multilayer Perceptron: Architecture Optimization and Training. Int J Interact Multim Artif Intell. 2016;4:26–30.
 
12.
Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. Jama. 2013;310:2061–2068.
 
13.
P PA, Kumari S, Rajasimman AS, Nayak S, Priyadarsini P. Machine learning predictive models of LDL-C in the population of eastern India and its comparison with directly measured and calculated LDL-C. Ann Clin Biochem. 2022;59:76–86.
 
14.
Tsigalou C, Panopoulou M, Papadopoulos C, Karvelas A, Tsairidis D, Anagnostopoulos K. Estimation of low-density lipoprotein cholesterol by machine learning methods. Clin Chim. Acta. 2021;517:108–116.
 
15.
Singh G, Hussain Y, Xu Z, et al. Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation. PLoS One. 2020;15:0239934.
 
16.
Sezer S, Oter A, Ersoz B, et al. Explainable artificial intelligence for LDL cholesterol prediction and classification. Clin Biochem. 2024:110791.
 
17.
Öter A. Deep learning-based LDL-C level prediction and explainable AI interpretation. Comput Biol Med. 2025;188:109905.
 
Journals System - logo
Scroll to top